Inflammatory Bowel Disease

References

1. ↵
   1. Satya-Murti S

   Rectal fumigation. A core rewarming practice from the past. Pharos Alpha Omega Alpha Honor Med So. 2005;68(1):35-38.

   OpenUrl
2. ↵
   1. Danese S,
   2. Fiocchi C

   Ulcerative colitis. N Engl J Med. 2011;365(18):1713-1725.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Loddo I,
   2. Romano C

   Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol. 2015;6:551.

   OpenUrlPubMed
4. ↵
   1. Molodecky NA,
   2. Soon IS,
   3. Rabi DM, et al.

   Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Ponder A,
   2. Long MD

   A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol. 2013;5:237-247.

   OpenUrl
6. ↵
   1. American College of Gastroenterology (ACG)

   Clinical Guidelines (Sortable List). ACG website. http://gi.org/clinical-guidelines/clinical-guidelines-sortable-list/. Accessed April 4, 2016.
7. ↵
   1. Feagan B

   A cluster randomized controlled trial of a treatment algorithm for the management of Crohn's disease. Identifier no. NCT01030809. Clinical Trials website. https://clinicaltrials.gov/ct2/show/NCT01030809. Accessed March 7, 2016.
8. ↵
   1. Williams C,
   2. Panaccione R,
   3. Ghosh S,
   4. Rioux K

   Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4(4):237-248.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Herfarth H

   Methotrexate in induction and maintenance of steroid free remission in ulcerative colitis (Merit-UC). Identifier no. NCT01393405. Clinical Trials website. https://clinicaltrials.gov/ct2/show/NCT01393405. Accessed March 7, 2016.
10. ↵
    1. Feagan BG,
    2. Rutgeerts P,
    3. Sands BE, et al.

    Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Lichtenstein GR,
    2. Hanauer SB,
    3. Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology

    Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104(2):465-483.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Colombel JF,
    2. Sandborn WJ,
    3. Reinisch W, et al.

    Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-1395.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Sandborn WJ,
    2. Feagan BG,
    3. Rutgeerts P, et al.

    Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-721.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Sandborn WJ,
    2. Gasin C,
    3. Gao LL, et al.

    Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367(16):1519-1528.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Sandborn WJ,
    2. Rutgeerts P,
    3. Feagan BG, et al.

    Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250-1260.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Kantso B,
    2. Simonsen J,
    3. Hoffman S, et al.

    Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977–2013. Am J Gastroenterol. 2015;110(11):1582-1587.

    OpenUrlPubMed
17. ↵
    1. Rahier JF,
    2. Magro F,
    3. Abreu C, et al., European Crohn's and Colitis Organisation (ECCO)

    Second European evidence-based consensus on the prevention, diagnosis, and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443-468.

    OpenUrlFREE Full Text
18. 1. Christensen KR,
    2. Steenholdt C,
    3. Buhl SS,
    4. Ainsworth MA,
    5. Thomsen O,
    6. Brynskov J

    Systematic information to health-care professionals about vaccination guidelines improves adherence in patients with inflammatory bowel disease in anti-TNFα therapy. Am J Gastroenterol 2015;110(11):1526-1532.

    OpenUrlPubMed
19. ↵
    1. Reddy KR,
    2. Beavers KL,
    3. Hammond SP,
    4. Lim JK,
    5. Falck-Ytter YT, American Gastroenterological Association Institute

    American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215-219.

    OpenUrlCrossRefPubMed
20. ↵
    1. Bjarnason I

    Metabolic bone disease in patients with inflammatory bowel disease. Rheumatology (Oxford). 1999;38(9):801-804.

    OpenUrlFREE Full Text
21. ↵
    1. Vagianos K,
    2. Bector S,
    3. McConnell J,
    4. Bernstein CN

    Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007;31(4):311-319.

    OpenUrlAbstract/FREE Full Text